Ratings Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Market Closed - Australian S.E. Other stock markets 02:10:44 2024-04-26 am EDT			5-day change	1st Jan Change
0.03 ^AUD	+3.45%		+3.45%	+36.36%

Apr. 22	Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	CI
Apr. 22	Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past twelve months, EPS forecast has been revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ACTINOGEN MEDICAL LIMITED	+36.36%	45.52M	-
IQVIA HOLDINGS INC.	+1.51%	42.75B	B
LONZA GROUP AG	+49.22%	41.61B	A
MODERNA, INC.	+8.57%	41.34B	B-
CELLTRION, INC.	-12.36%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B	B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+6.35%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes